Prognostic Value of Molecular Breast Cancer Subtypes based on Her2, ESR1, PGR and Ki67 mRNA-Expression in Muscle Invasive Bladder Cancer.

about

Prognostic Value of Molecular Breast Cancer Subtypes based on Her2, ESR1, PGR and Ki67 mRNA-Expression in Muscle Invasive Bladder Cancer.

Item

http://www.wikidata.org/entity/Q55005107

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Prognostic Value of Molecular ...... uscle Invasive Bladder Cancer.

@en

Prognostic Value of Molecular ...... uscle Invasive Bladder Cancer.

@nl

type

Item

label

Prognostic Value of Molecular ...... uscle Invasive Bladder Cancer.

@en

Prognostic Value of Molecular ...... uscle Invasive Bladder Cancer.

@nl

prefLabel

Prognostic Value of Molecular ...... uscle Invasive Bladder Cancer.

@en

Prognostic Value of Molecular ...... uscle Invasive Bladder Cancer.

@nl

P1476

Prognostic Value of Molecular ...... uscle Invasive Bladder Cancer.

@en

P2093

A Hartmann

http://www.w3.org/2001/XMLSchema#string

B Keck

http://www.w3.org/2001/XMLSchema#string

C A Weis

http://www.w3.org/2001/XMLSchema#string

C Boehmer

http://www.w3.org/2001/XMLSchema#string

C Bolenz

http://www.w3.org/2001/XMLSchema#string

J Breyer

http://www.w3.org/2001/XMLSchema#string

M C Kriegmair

http://www.w3.org/2001/XMLSchema#string

M Eckstein

http://www.w3.org/2001/XMLSchema#string

M Ritter

http://www.w3.org/2001/XMLSchema#string

P Erben

http://www.w3.org/2001/XMLSchema#string

P2860

Steroid Hormone Receptor Signals as Prognosticators for Urothelial Tumor

New strategies in breast cancer: the significance of molecular subtypes in systemic adjuvant treatment for small T1a,bN0M0 tumors

High Ki-67 Immunohistochemical Reactivity Correlates With Poor Prognosis in Bladder Carcinoma: A Comprehensive Meta-Analysis with 13,053 Patients Involved

Repeated observation of breast tumor subtypes in independent gene expression data sets

Comprehensive molecular characterization of urothelial bladder carcinoma

Predictive and prognostic molecular markers for cancer medicine

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial.

Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy

Advanced urothelial carcinoma: next-generation sequencing reveals diverse genomic alterations and targets of therapy.

P304

467-476

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.TRANON.2018.02.001

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-02-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29477637

http://www.w3.org/2001/XMLSchema#string

P932

5834659

http://www.w3.org/2001/XMLSchema#string